Structure Therapeutics stock rating reiterated at Buy by H.C. Wainwright

Investing.com - H.C. Wainwright reiterated its Buy rating on Structure Therapeutics (NASDAQ:GPCR) on Monday, maintaining its price target of $75.00 per share, representing significant upside from the current price of $21.73. According to InvestingPro data, analyst targets range from $37.50 to $120.00, with a strong consensus recommendation of 1.43 (Buy).

The reaffirmation follows data presented from the ACHIEVE-1 trial at the 85th American Diabetes Association Conference in Chicago on Saturday, which highlighted the potential of oral GLP-1R agonists in diabetes treatment.

Dr. Julio Rosenstock, who presented the ACHIEVE-1 trial results, noted that oral drugs like orforglipron (OFG) "might become first-line treatments" based on the trial data, according to H.C. Wainwright.

The research firm discussed implications of the ACHIEVE-1 results for Structure Therapeutics’ aleniglipron ACCESS trial, which is scheduled to report results in the fourth quarter of 2025.

H.C. Wainwright analyst Ananda Ghosh maintained the firm’s $75 price target on Structure Therapeutics shares while reiterating the Buy rating.

In other recent news, Structure Therapeutics has been the focus of several analyst evaluations and developments in the pharmaceutical landscape. Citi initiated coverage of Structure Therapeutics with a Buy rating and a $60 price target, highlighting the potential of its lead drug candidate, aleniglipron, which is in Phase 2b trials for obesity. H.C. Wainwright reaffirmed its Buy rating and $80 price target, noting aleniglipron’s promising profile and potential for substantial weight loss in upcoming trials. JMP Securities maintained its Market Outperform rating with an $89 price target, pointing to the anticipated Phase 2b data for aleniglipron as a significant point of interest.

Additionally, Structure Therapeutics’ stock received a boost after Pfizer (NYSE:PFE) announced the discontinuation of its obesity drug candidate, danuglipron, due to liver toxicity concerns. This development potentially reduces competition for Structure Therapeutics in the obesity treatment market. Analysts at JMP also expressed optimism about the upcoming data on another drug candidate, orforglipron, which could impact the company’s share performance if safety and efficacy benchmarks are met. As Structure Therapeutics progresses with its clinical trials, these developments have positioned the company as a noteworthy player in the obesity and metabolic disorder treatment space.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.